|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM359343910 |
| 003 |
DE-627 |
| 005 |
20231226080654.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231226s2023 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2023.109694
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1197.xml
|
| 035 |
|
|
|a (DE-627)NLM359343910
|
| 035 |
|
|
|a (NLM)37433424
|
| 035 |
|
|
|a (PII)S1521-6616(23)00457-6
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Xia, RuiYuan
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Local injection of micro-dose anti-interleukin-17A antibody for palmoplantar pustulosis
|b A real-world study
|
| 264 |
|
1 |
|c 2023
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 26.07.2023
|
| 500 |
|
|
|a Date Revised 26.07.2023
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2023 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a Palmoplantar pustulosis (PPP), a chronic and stubborn skin disease, is mainly confined to the palms or/and soles, making it possible for localized use of therapeutic antibodies. In this real-world prospective cohort study, 8 patients with PPP received palms/soles injections of ixekizumab (0.8 mg in 0.1 ml) every 2 to 8 weeks due to the COVID-19 pandemic. The treatment endpoint was a 75% improvement from baseline in Palmoplantar Pustulosis/Psoriasis Area and Severity Index (PPPASI 75). At week 8, 75%, 50% and 12.5% of 8 patients reached PPPASI 50, PPPASI 75 and PPPASI 90. At week 12, 100%, 75% and 25% of 8 patients reached PPPASI 50, PPPASI 75 and PPPASI 90. This is the first study to evaluate the efficacy and safety of local injection of micro-dose ixekizumab for PPP in real clinical practice. A high proportion of patients rapidly achieved PPPASI 75, and maintained long-term efficacy with satisfactory safety
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a IL-17
|
| 650 |
|
4 |
|a Ixekizumab
|
| 650 |
|
4 |
|a Local injection
|
| 650 |
|
4 |
|a Palmoplantar pustulosis
|
| 650 |
|
4 |
|a Psoriasis
|
| 700 |
1 |
|
|a Liu, Jian
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Gao, YaMei
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Diao, ZiYue
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Chen, DanDan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhou, ChaoJing
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhang, ZhiQin
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yin, ZhiQiang
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 253(2023) vom: 30. Aug., Seite 109694
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:253
|g year:2023
|g day:30
|g month:08
|g pages:109694
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2023.109694
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 253
|j 2023
|b 30
|c 08
|h 109694
|